Terazosin 5mg tablets

Država: Velika Britanija

Jezik: angleščina

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Aktivna sestavina:

Terazosin hydrochloride

Dostopno od:

Teva UK Ltd

Koda artikla:

G04CA03

INN (mednarodno ime):

Terazosin hydrochloride

Odmerek:

5mg

Farmacevtska oblika:

Oral tablet

Pot uporabe:

Oral

Razred:

No Controlled Drug Status

Tip zastaranja:

Valid as a prescribable product

Povzetek izdelek:

BNF: 02050400; GTIN: 5017007012160

Navodilo za uporabo

ZINC Ref:
EAS4735B LEA TERAZOSIN 2MG 5MG 10MG TAB TUK

Preberite celoten dokument

Lastnosti izdelka

1.
NAME OF THE MEDICINAL PRODUCT
Terazosin 5 mg Tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 5.935 mg of terazosin hydrochloride dihydrate
equivalent to 5mg of
terazosin.
For excipients see 6.1.
3.
PHARMACEUTICAL FORM
Tablet
Mottled tan, round, flat tablet with bevelled edges, embossed with
“93” on one-side and
“762” on the other side
4.
CLINICAL PARTICULARS
4.1.
THERAPEUTIC INDICATIONS
Terazosin Tablets are indicated for:
The treatment of mild to moderate hypertension.
The symptomatic treatment of urinary obstruction caused by benign
prostatic hyperplasia
(BPH).
4.2.
POSOLOGY AND METHOD OF ADMINISTRATION.
For oral use.
For the different dosage regimens suitable strengths are available.
The dose of terazosin
should be adjusted according to the patient's response. The following
is a guide to
administration:
INITIAL DOSE:
The lowest single dose of 1 mg before bedtime for all patients which
should not be
exceeded. Strict compliance with this recommendation should be
observed to minimise
potential acute first-dose hypotensive episodes.
SUBSEQUENT DOSES:
Treatment of mild to moderate hypertension.
The single daily dosage may be increased by approximately doubling the
dosage at weekly
intervals to achieve the desired blood pressure response.
The maintenance dose needs to be adjusted to the patient’s response.
2 mg/day may be
sufficient with increases up to 10 mg if necessary (clinical studies
support the use of 2-10
mg as maintenance dose).
The maximum dose is 20 mg of terazosin per day and should not be
exceeded.
Use with thiazide diuretics and other antihypertensive agents in the
treatment of
hypertension
When adding a thiazide diuretic or another antihypertensive agent to a
patient's regimen the
dose of terazosin should be reduced or discontinued and retitration
carried out if necessary.
Caution should be observed when terazosin is administered with
thiazides or other
antihypertensive agents as hypotension may develop.
Treatment of benign prostatic hyperplasia
The dose may be in